A Study to Determine the Safety and Efficacy of Albiglutide Administered in Combination With Insulin Glargine

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
GlaxoSmithKline
ClinicalTrials.gov Identifier:
NCT00976391
First received: September 11, 2009
Last updated: July 31, 2014
Last verified: June 2014
  Purpose

This study will examine the safety and efficacy of albiglutide in combination with insulin glargine as compared with the combination of insulin glargine and preprandial lispro insulin in subjects with type 2 diabetes.


Condition Intervention Phase
Diabetes Mellitus, Type 2
Biological: albiglutide + insulin glargine
Drug: insulin glargine + preprandial lispro insulin
Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: A Randomized, Open-Label, Active-Controlled, Parallel-Group, Multicenter Study to Determine the Safety and Efficacy of Albiglutide Administered in Combination With Insulin Glargine as Compared With the Combination of Insulin Glargine and Preprandial Lispro Insulin in Subjects With Type 2 Diabetes Mellitus

Resource links provided by NLM:


Further study details as provided by GlaxoSmithKline:

Primary Outcome Measures:
  • Change From Baseline (BL) in Glycosylated Hemoglobin (HbA1c) at Week 26 [ Time Frame: Baseline and Week 26 ] [ Designated as safety issue: No ]
    HbA1c is a form of hemoglobin that is measured primarily to identify the average plasma glucose concentration over a 2- to 3-month period. The BL HbA1c value is defined as the last non-missing value before the start of treatment. Change from BL was calculated as the value at Week 26 minus the value at BL. The analysis was performed using an Analysis of Covariance (ANCOVA) model with treatment group, region, history of prior myocardial infarction (yes versus no), and age category (<65 years versus ≥65 years) as factors and Baseline HbA1c as a continuous covariate.The last observation carried forward (LOCF) method was used to impute missing post-BL HbA1c values; the last non-missing post-BL on-treatment measurement was used to impute the missing measurement. HbA1c values obtained after hyperglycemic rescue were treated as missing and were replaced with pre-rescue values.


Secondary Outcome Measures:
  • Change From Baseline in HbA1c at Weeks 36, 48 and 52 [ Time Frame: Baseline and Weeks 36, 48 and 52 ] [ Designated as safety issue: No ]
    HbA1c is a form of hemoglobin that is measured primarily to identify the average plasma glucose concentration over a 2- to 3-month period. Baseline is defined as the last available assessment on or prior to the first dose of study drug. Change from Baseline was calculated as the post-Baseline value minus the Baseline value. This analysis used observed HbA1c values, excluding those obtained after hyperglycemia rescue; no missing data imputation was performed.

  • Change From Baseline in Fasting Plasma Glucose (FPG) at Week 26 [ Time Frame: Baseline and Week 26 ] [ Designated as safety issue: No ]
    The FPG test measures blood sugar levels after the participant has not eaten (fasted) for 12 to 14 hours. The Baseline FPG value is the last non-missing value before the start of treatment. The LOCF method was used to impute missing post-Baseline FPG values. FPG values obtained after hyperglycemia rescue were treated as missing and replaced with pre-rescue values. Change from Baseline was calculated as the post-Baseline value minus the Baseline value. Based on ANCOVA: change = treatment + Baseline FPG + Baseline HbA1c category + region

  • Change From Baseline in Fasting Plasma Glucose (FPG) at Weeks 36, 48 and 52 [ Time Frame: Baseline and Weeks 36, 48 and 52 ] [ Designated as safety issue: No ]
    The FPG test measures blood sugar levels after the participant has not eaten (fasted) for 12 to 14 hours. The Baseline FPG value is the last non-missing value before the start of treatment. Change from Baseline was calculated as the post-Baseline FPG minus the Baseline FPG. This analysis used observed FPG values excluding those obtained after hyperglycemia rescue; no missing data imputation was performed.

  • Number of Participants Who Achieved HbA1c Response Level of <6.5% and <7.0% at Week 26 [ Time Frame: Week 26 ] [ Designated as safety issue: No ]
    The number of participants who acheieved the HbA1c treatment goal (i.e., HbA1c response levels of <6.5% and <7.0% at Week 26) were assessed.

  • Time to Hyperglycemia Rescue [ Time Frame: From the start of study medication until the end of the treatment (up to Week 52) ] [ Designated as safety issue: No ]
    Participants who experienced persistent hyperglycemia (high blood glucose) could have qualified for hyperglycemia rescue. The conditions for hyperglycemia rescue were as follows: HbA1c >9.0% and <0.5% decrease from Baseline between >=Week 4 and <Week 8; HbA1c >9.0% and <0.5% decrease from Baseline between >=Week 8 and <Week 12; HbA1c >8.5% and >=4 weeks since uptitration between >=Week 12 and <Week 16; HbA1c >8.0% and >=4 weeks since uptitration; HbA1c >7.5% and >=4 weeks between >Week 26 and >=Week 48 since uptitration. Participants could have been rescued at any time after Week 4. Time to hyperglycemia rescue is the time between the date of first dose and the date of hyperglycemia rescue plus 1 day, or the time between the date of first dose and the date of last visit during active treatment period plus 1 day for participants not requiring rescue. This time is divided by 7 to express the result in weeks.

  • Change From Baseline in Body Weight at Week 26 [ Time Frame: Baseline and Week 26 ] [ Designated as safety issue: No ]
    The Baseline value is the last non-missing value before the start of treatment. Change from Baseline was calculated as the post-Baseline weight minus the Baseline weight. The LOCF method was used to impute missing post-Baseline weight values. Weight values obtained after hyperglycemia rescue were treated as missing and replaced with prerescue values. Based on ANCOVA: change = treatment + Baseline weight + Baseline HbA1c category + prior myocardial infarction history + age category + region + current oral antidiabetic therapy.

  • Change From Baseline in Body Weight at Weeks 36, 48 and 52 [ Time Frame: Baseline and Weeks 36, 48 and 52 ] [ Designated as safety issue: No ]
    The Baseline value is the last non-missing value before the start of treatment. Change from Baseline was calculated as the post-Baseline weight minus the Baseline weight. This analysis used observed body weight values excluding those obtained after hyperglycemia rescue; no missing data imputation was performed.


Enrollment: 586
Study Start Date: September 2009
Study Completion Date: October 2011
Primary Completion Date: October 2011 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Active Comparator: albiglutide + insulin glargine
albiglutide in combination with insulin glargine
Biological: albiglutide + insulin glargine
albiglutide in combination with insulin glargine
Active Comparator: insulin glargine + preprandial lispro insulin
insulin glargine in combination with preprandial lispro insulin
Drug: insulin glargine + preprandial lispro insulin
insulin glargine in combination with preprandial lispro insulin

Detailed Description:

This randomized, open-label, active-controlled, parallel-group, multicenter study evaluates the safety and efficacy of a weekly subcutaneously injected dose of albiglutide in combination with insulin glargine as compared with the combination of insulin glargine and preprandial lispro insulin in subjects with type 2 diabetes. Subjects with a historical diagnosis of type 2 diabetes who are inadequately controlled despite the use of insulin glargine or other intermediate- or long-acting insulins for >/= 6 months but < 5 years, with or without oral antidiabetic medications, who are unable to achieve a glycosylated hemoglobin value of < 7% will be recruited into the study. Subjects must also be willing and capable of pursuing an intensive regimen of both basal and preprandial insulin.

  Eligibility

Ages Eligible for Study:   18 Years to 75 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Subjects with type 2 diabetes, currently treated with insulin glargine or other intermediate- or long-acting insulin, with or without oral antidiabetic medications, but experiencing inadequate glycemic control and willing and capable of participating in a regimen of intensive insulin administration. A subject who has been on an intermediate- or long acting insulin for >/=6 months but <5 years, and, in spite of dosage adjustments based on home blood glucose monitoring, is unable to achieve a HbA1c of <7%.
  • BMI >/= 20kg/m2 and </=45 kg/m2
  • Fasting C-peptide >/=0.8 ng/mL (>/= 0.26 nmol/L)
  • HbA1c between 7.0% and 10.5%, inclusive
  • Use of oral or systemically injected glucocorticoids is generally not allowed within 3 months before randomization; inhaled, intra articular, and topical corticosteroids are allowed
  • Hemoglobin </=11 g/dL for male subjects and >/=10 g/dL for female subjects
  • Creatinine clearance >60 mL/min (calculated using the Cockcroft Gault formula)
  • Thyroid stimulating hormone level is normal or clinically euthyroid as demonstrated by further thyroid tests (e.g., T4, T3, thyroid-binding globulin)
  • Female subjects of childbearing potential (i.e., not surgically sterile and/or not postmenopausal) must be practicing adequate contraception. Adequate contraception must be practiced for the duration of participation in the study including the 8 week Posttreatment Follow-up Period
  • Able and willing to monitor his or her own blood glucose concentrations with a home glucose monitor as per the protocol recommendations of self administration
  • No major illness or debility that in the investigator's opinion prohibits the subject from actively participating in their diabetes management and completing the study
  • Able and willing to provide written informed consent

Exclusion Criteria:

  • History of cancer, other than squamous cell or basal cell carcinoma of the skin, that has not been in full remission for at least 3 years before Screening.
  • History of treated diabetic gastroparesis
  • Current ongoing symptomatic biliary disease or history of pancreatitis
  • History of significant gastrointestinal surgery, including gastric bypass and banding, antrectomy, Roux en Y bypass, gastric vagotomy, small bowel resection, or surgeries thought to significantly affect upper gastrointestinal function
  • Recent clinically significant cardiovascular and/or cerebrovascular disease including but not limited to the following:

    • Previous history of stroke or transient ischemic attack within 1 month before Screening.
    • Acute coronary syndrome, which includes the following:
    • Documented MI within the 2 months before Screening and during the period up until receiving the first dose of study medication
    • Any cardiac surgery including percutaneous transluminal coronary angioplasty, coronary stent placement, or coronary artery bypass graft surgery within the 2 months before Screening and during the period up until receiving the first dose of study medication
    • Unstable angina not responsive to nitroglycerin within the 2 months before Screening and during the period up until receiving the first dose of study medication
    • Unstable cardiac rhythm, however, as an example, controlled atrial fibrillation is allowed
    • Current or history of heart failure (New York Heart Association class I to IV).
    • Resting systolic pressure is >160 mm Hg and/or diastolic pressure >100 mm Hg.
    • QTc interval (Fridericia) >470 ms confirmed by a central reader at Screening
  • History of stroke or other central nervous system disorder that would negatively impact the subject's ability to participate in a program of intensive insulin management (eg, physically or mentally incapable of performing home blood glucose monitoring or administering and/or adjusting insulin dosage)
  • Hemoglobinopathy that may affect determination of HbA1c
  • History of human immunodeficiency virus infection
  • History of total bilirubin >1.5 × ULN unless the subject has a previously known history of Gilbert's syndrome and a fractionated bilirubin that shows conjugated bilirubin <35% of total bilirubin
  • ALT or aspartate aminotransferase (AST) >2.5 ×ULN
  • Fasting triglyceride level >850 mg/dL at Screening or Week -1 (Visit 5).
  • Acute symptomatic (within 3 months before Screening) infection with hepatitis B or hepatitis C; however, subjects with past or chronic hepatitis B or hepatitis C are allowed provided the requirements for ALT, AST, and total bilirubin are met
  • History of a psychiatric disorder that will affect the subject's ability to participate in the study
  • History of alcohol or substance abuse within 1 year before Screening
  • Positive urine drug screen at Screening, unless the subject is taking a medically approved medication for which a positive drug screen simply verifies the use of this medication
  • Hypoglycemia unawareness which has impaired cognitive function and required outside assistance
  • Female subject is pregnant (confirmed by laboratory testing), lactating, or <6 weeks postpartum
  • Known allergy to any GLP 1 analogue, insulin, other study medications' excipients, excipients of albiglutide, or Baker's yeast
  • Receipt of any investigational drug within the 30 days, or 5 half lives whichever is longer, before Screening or a history of receipt of an investigational antidiabetic drug within the 3 months before randomization, or receipt of albiglutide in previous studies
  • Current use of any GLP 1 analogue
  • History of type 1 diabetes mellitus, diabetic complications (e.g., active proliferative retinopathy or severe diabetic neuropathy) that in the opinion of the investigator would preclude effective participation in the study, or a history of ketoacidosis or hyperosmolar coma
  • Contraindications (as per the prescribing information) for the use of either background or potential randomized study medications (e.g., insulin glargine or lispro insulin)
  • History or family history of medullary carcinoma
  • History or family history of multiple endocrine neoplasia type 2
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00976391

  Hide Study Locations
Locations
United States, Alabama
GSK Investigational Site
Birmingham, Alabama, United States, 35205
GSK Investigational Site
Dothan, Alabama, United States, 36301
United States, Arizona
GSK Investigational Site
Gilbert, Arizona, United States, 85295
GSK Investigational Site
Phoenix, Arizona, United States, 85028
GSK Investigational Site
Phoenix, Arizona, United States, 85050
United States, Arkansas
GSK Investigational Site
Jonesboro, Arkansas, United States, 72401
GSK Investigational Site
Searcy, Arkansas, United States, 72143
United States, California
GSK Investigational Site
Chino, California, United States, 91710
GSK Investigational Site
Commerce, California, United States, 90040
GSK Investigational Site
Fresno, California, United States, 93720
GSK Investigational Site
Fullerton, California, United States, 92835
GSK Investigational Site
Huntington Beach, California, United States, 92646
GSK Investigational Site
La Jolla, California, United States, 92037
GSK Investigational Site
LaJolla, California, United States, 92037
GSK Investigational Site
Long Beach, California, United States, 90806
GSK Investigational Site
Los Alamitos, California, United States, 90720
GSK Investigational Site
Los Angeles, California, United States, 90073
GSK Investigational Site
Mission Viejo, California, United States, 92691
GSK Investigational Site
Sacramento, California, United States, 95821
GSK Investigational Site
San Diego, California, United States, 92117
GSK Investigational Site
San Diego, California, United States, 92128
GSK Investigational Site
San Diego, California, United States, 92161
GSK Investigational Site
Satna Monica, California, United States, 90404
GSK Investigational Site
Spring Valley, California, United States, 91978
GSK Investigational Site
Tustin, California, United States, 92780
GSK Investigational Site
Walnut Creek, California, United States, 94598
GSK Investigational Site
West Hills, California, United States, 91307
United States, Colorado
GSK Investigational Site
Denver, Colorado, United States, 80220
United States, Connecticut
GSK Investigational Site
New Britain, Connecticut, United States, 06050
GSK Investigational Site
Trumbull, Connecticut, United States, 06611
GSK Investigational Site
Waterbury, Connecticut, United States, 06708
United States, Florida
GSK Investigational Site
Boynton Beach, Florida, United States, 33437
GSK Investigational Site
Clearwater, Florida, United States, 33756
GSK Investigational Site
Cutler Bay, Florida, United States, 33189
GSK Investigational Site
Hallandale Beach, Florida, United States, 33009
GSK Investigational Site
Jacksonville, Florida, United States, 32205
GSK Investigational Site
Lauderdale Lakes, Florida, United States, 33319
GSK Investigational Site
Miami, Florida, United States, 33156
GSK Investigational Site
Orlando, Florida, United States, 32822
GSK Investigational Site
Plantation, Florida, United States, 33317
GSK Investigational Site
West Palm Beach, Florida, United States, 33401
United States, Georgia
GSK Investigational Site
Atlanta, Georgia, United States, 30338
GSK Investigational Site
Atlanta, Georgia, United States, 30308
GSK Investigational Site
Blue Ridge, Georgia, United States, 30513
GSK Investigational Site
Columbus, Georgia, United States, 31904
GSK Investigational Site
Savannah, Georgia, United States, 31419
GSK Investigational Site
Snellville, Georgia, United States, 30078
United States, Hawaii
GSK Investigational Site
Honolulu, Hawaii, United States, 96813
GSK Investigational Site
Honolulu, Hawaii, United States, 96814
United States, Idaho
GSK Investigational Site
Idaho Falls, Idaho, United States, 83404
United States, Illinois
GSK Investigational Site
La Grange, Illinois, United States, 60525
United States, Indiana
GSK Investigational Site
Avon, Indiana, United States, 46123
GSK Investigational Site
Evansville, Indiana, United States, 47714
GSK Investigational Site
Lafayette, Indiana, United States, 47904
United States, Iowa
GSK Investigational Site
Council Bluffs, Iowa, United States, 51501
GSK Investigational Site
Des Moines, Iowa, United States, 50314
GSK Investigational Site
Iowa City, Iowa, United States, 52243
United States, Kansas
GSK Investigational Site
Newton, Kansas, United States, 67114
GSK Investigational Site
Topeka, Kansas, United States, 66606
United States, Kentucky
GSK Investigational Site
Lexington, Kentucky, United States, 40504
GSK Investigational Site
Lexington, Kentucky, United States, 40503
United States, Louisiana
GSK Investigational Site
Shreveport, Louisiana, United States, 71101
United States, Maryland
GSK Investigational Site
Hyattsville, Maryland, United States, 20782
United States, Massachusetts
GSK Investigational Site
Haverhill, Massachusetts, United States, 01830
United States, Michigan
GSK Investigational Site
Ann Arbor, Michigan, United States, 48106
GSK Investigational Site
Benzonia, Michigan, United States, 49616
GSK Investigational Site
Bloomfield Hills, Michigan, United States, 48302
GSK Investigational Site
Dearborn, Michigan, United States, 48124
GSK Investigational Site
Kalamazoo, Michigan, United States, 49009
GSK Investigational Site
Kalamazoo, Michigan, United States, 49048
United States, Mississippi
GSK Investigational Site
Picayune, Mississippi, United States, 39466
United States, Missouri
GSK Investigational Site
Chesterfield, Missouri, United States, 63017
GSK Investigational Site
Jefferson City, Missouri, United States, 65109
GSK Investigational Site
Kansas City, Missouri, United States
GSK Investigational Site
Springfield, Missouri, United States, 65807
GSK Investigational Site
St. Louis, Missouri, United States, 63110
GSK Investigational Site
St. Louis, Missouri, United States, 63141
United States, Montana
GSK Investigational Site
Great Falls, Montana, United States, 59405
United States, Nebraska
GSK Investigational Site
Omaha, Nebraska, United States, 68131
GSK Investigational Site
Omaha, Nebraska, United States, 68124
United States, New Jersey
GSK Investigational Site
Haddon Heights, New Jersey, United States, 08035
United States, New York
GSK Investigational Site
New York, New York, United States, 10025
GSK Investigational Site
North Massapequa, New York, United States, 11758
United States, North Carolina
GSK Investigational Site
Asheville, North Carolina, United States, 28803
GSK Investigational Site
Burlington, North Carolina, United States, 27215
GSK Investigational Site
Durham, North Carolina, United States, 27710
GSK Investigational Site
Hickory, North Carolina, United States, 28601
GSK Investigational Site
Morehead City, North Carolina, United States, 28557
GSK Investigational Site
Tabor City, North Carolina, United States, 28463
United States, Ohio
GSK Investigational Site
Akron, Ohio, United States, 44320
GSK Investigational Site
Canal Fulton, Ohio, United States, 44614
GSK Investigational Site
Cincinnati, Ohio, United States, 45245
GSK Investigational Site
Cleveland, Ohio, United States, 44122
GSK Investigational Site
Columbus, Ohio, United States, 43213
GSK Investigational Site
Dayton, Ohio, United States, 45439
United States, Oklahoma
GSK Investigational Site
Oklahoma City, Oklahoma, United States, 73104
GSK Investigational Site
Oklahoma City, Oklahoma, United States, 73103
GSK Investigational Site
Tulsa, Oklahoma, United States, 74104
GSK Investigational Site
Tulsa, Oklahoma, United States, 74136
United States, Pennsylvania
GSK Investigational Site
Bensalem, Pennsylvania, United States, 19020
GSK Investigational Site
Carlisle, Pennsylvania, United States, 17013
GSK Investigational Site
Tipton, Pennsylvania, United States, 16684
GSK Investigational Site
Uniontown, Pennsylvania, United States, 15401
United States, South Carolina
GSK Investigational Site
Greenville, South Carolina, United States, 29601
GSK Investigational Site
Greenville, South Carolina, United States, 29615
GSK Investigational Site
Murrells Inlet, South Carolina, United States, 29576
United States, Tennessee
GSK Investigational Site
Clarksville, Tennessee, United States, 37043
GSK Investigational Site
Johnson City, Tennessee, United States, 37604
GSK Investigational Site
McKenzie, Tennessee, United States, 38201
GSK Investigational Site
Memphis, Tennessee, United States, 38125
GSK Investigational Site
Tullahoma, Tennessee, United States, 37398
United States, Texas
GSK Investigational Site
Arlington, Texas, United States, 76012
GSK Investigational Site
Bedford, Texas, United States, 76201
GSK Investigational Site
Corpus Christi, Texas, United States, 78404
GSK Investigational Site
Dallas, Texas, United States, 75251
GSK Investigational Site
Dallas, Texas, United States, 75224
GSK Investigational Site
Dallas, Texas, United States, 75230
GSK Investigational Site
Dallas, Texas, United States, 75246
GSK Investigational Site
El Paso, Texas, United States, 79925
GSK Investigational Site
Houston, Texas, United States, 77074
GSK Investigational Site
Houston, Texas, United States, 77024
GSK Investigational Site
Houston, Texas, United States, 77030
GSK Investigational Site
Houston, Texas, United States, 77058
GSK Investigational Site
Katy, Texas, United States, 77450
GSK Investigational Site
Lake Jackson, Texas, United States, 77566
GSK Investigational Site
Midland, Texas, United States, 79707
GSK Investigational Site
North Richland Hills, Texas, United States, 76180
GSK Investigational Site
San Antonio, Texas, United States, 78218
GSK Investigational Site
San Antonio, Texas, United States, 78215
GSK Investigational Site
Schertz, Texas, United States, 78154
GSK Investigational Site
Sugar Land, Texas, United States, 77478
GSK Investigational Site
Temple, Texas, United States, 76508
United States, Utah
GSK Investigational Site
Bountiful, Utah, United States, 84010
GSK Investigational Site
Salt Lake City, Utah, United States, 84124
GSK Investigational Site
Salt Lake City, Utah, United States, 84102
United States, Vermont
GSK Investigational Site
South Burlington, Vermont, United States, 05403
United States, Virginia
GSK Investigational Site
Burke, Virginia, United States, 22015
GSK Investigational Site
Hampton, Virginia, United States, 23666
GSK Investigational Site
Manassas, Virginia, United States, 20110
GSK Investigational Site
Richmond, Virginia, United States, 23294
United States, Washington
GSK Investigational Site
Spokane, Washington, United States, 99216
GSK Investigational Site
Tacoma, Washington, United States, 98405
United States, West Virginia
GSK Investigational Site
Lewisburg, West Virginia, United States, 24901
Brazil
GSK Investigational Site
Porto Alegre, Rio Grande Do Sul, Brazil, 90035-170
GSK Investigational Site
Brasília, Brazil, 71625-009
GSK Investigational Site
Mogi das Cruzes, Brazil, 08780 - 090
France
GSK Investigational Site
Armentières, France, 59280
GSK Investigational Site
Venissieux, France, 69200
Germany
GSK Investigational Site
Witten, Nordrhein-Westfalen, Germany, 58455
GSK Investigational Site
Mainz, Rheinland-Pfalz, Germany, 55116
GSK Investigational Site
Dresden, Sachsen, Germany, 01307
GSK Investigational Site
Berlin, Germany, 10115
Hong Kong
GSK Investigational Site
Shatin, Hong Kong
India
GSK Investigational Site
Bangalore, India, 560043
GSK Investigational Site
Bangalore, India, 560 054
GSK Investigational Site
Bangalore, India, 560052
GSK Investigational Site
Chennai, India, 600020
GSK Investigational Site
Manipal, India, 576104
Korea, Republic of
GSK Investigational Site
Goyang-si, Korea, Republic of, 411706
GSK Investigational Site
Koyang-shi, Korea, Republic of, 411710
GSK Investigational Site
Seongnam-si, Korea, Republic of, 463712
GSK Investigational Site
Seongnam-si,, Korea, Republic of, 463-707
GSK Investigational Site
Seoul, Korea, Republic of, 137-701
GSK Investigational Site
Seoul, Korea, Republic of, 139-872
GSK Investigational Site
Seoul, Korea, Republic of, 135-720
GSK Investigational Site
Suwon, Kyonggi-do, Korea, Republic of, 443-721
Mexico
GSK Investigational Site
Pachuca, Hidalgo, Mexico, 42086
GSK Investigational Site
Mexico City, Mexico, 03300
GSK Investigational Site
Puebla, Mexico, 72190
Peru
GSK Investigational Site
Huacho, Lima, Peru
GSK Investigational Site
Ica, Peru, 11
GSK Investigational Site
Lima, Peru, 01
GSK Investigational Site
Piura, Peru
GSK Investigational Site
Trujillo, Peru
Philippines
GSK Investigational Site
Marikina City, Philippines, 1810
GSK Investigational Site
Pasay, Philippines, 1300
GSK Investigational Site
Pasig, Philippines, 1600
GSK Investigational Site
Quezon City, Philippines, 1102
GSK Investigational Site
San Juan, Philippines, 1500
GSK Investigational Site
Tagbilaran City, Philippines, 6300
GSK Investigational Site
Taytay Rizal, Philippines, 1920
South Africa
GSK Investigational Site
Port Elizabeth, Eastern Cape, South Africa, 6014
GSK Investigational Site
Boksburg North, Gauteng, South Africa, 1459
GSK Investigational Site
Johannesburg, Gauteng, South Africa, 2193
GSK Investigational Site
Johannesburg, Gauteng, South Africa, 2013
GSK Investigational Site
Johannesburg, Gauteng, South Africa, 01820
GSK Investigational Site
Lenasia, Gauteng, South Africa, 1827
GSK Investigational Site
Pretoria, Gauteng, South Africa, 00083
GSK Investigational Site
Durban, KwaZulu- Natal, South Africa, 4000
GSK Investigational Site
Durban, KwaZulu- Natal, South Africa, 4068
GSK Investigational Site
Bellville, South Africa, 7530
GSK Investigational Site
Cape Town, South Africa, 7530
GSK Investigational Site
Kempton Park, South Africa, 1619
GSK Investigational Site
Parow, South Africa, 7505
GSK Investigational Site
Somerset West, South Africa, 7130
Spain
GSK Investigational Site
Alzira, Spain, 46600
GSK Investigational Site
Barcelona, Spain, 08022
GSK Investigational Site
Madrid, Spain, 28034
GSK Investigational Site
Palma de Mallorca, Spain, 07010
GSK Investigational Site
Sabadell, Spain, 08208
GSK Investigational Site
Sevilla, Spain, 41003
Taiwan
GSK Investigational Site
Taichung, Taiwan, 404
GSK Investigational Site
Tainan, Taiwan, 71044
GSK Investigational Site
Taipei, Taiwan, 11490
GSK Investigational Site
Taipei, Taiwan, 100
GSK Investigational Site
Taipei County, Taiwan, 23137
United Kingdom
GSK Investigational Site
Liverpool, Merseyside, United Kingdom, L7 8XP
GSK Investigational Site
Hull, United Kingdom, HU3 2RW
GSK Investigational Site
London, United Kingdom, SE 1 9RT
GSK Investigational Site
Plymouth, United Kingdom, PL6 8BX
Sponsors and Collaborators
GlaxoSmithKline
Investigators
Study Director: GSK Clinical Trials GlaxoSmithKline
  More Information

No publications provided

Responsible Party: GlaxoSmithKline
ClinicalTrials.gov Identifier: NCT00976391     History of Changes
Other Study ID Numbers: 108486
Study First Received: September 11, 2009
Results First Received: May 1, 2014
Last Updated: July 31, 2014
Health Authority: United States: Food and Drug Administration

Keywords provided by GlaxoSmithKline:
open-label
albiglutide
insulin glargine
preprandial insulin

Additional relevant MeSH terms:
Diabetes Mellitus
Diabetes Mellitus, Type 2
Glucose Metabolism Disorders
Metabolic Diseases
Endocrine System Diseases
Insulin, Globin Zinc
Glargine
Insulin
Insulin Lispro
Insulin, Long-Acting
Albiglutide
Hypoglycemic Agents
Physiological Effects of Drugs
Pharmacologic Actions
Incretins
Hormones
Hormones, Hormone Substitutes, and Hormone Antagonists

ClinicalTrials.gov processed this record on August 19, 2014